Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression

Leukemia Research

Volumn 30, Issue 12, 2006, Pages 1471-1491

  Bolufer, Pascual ^a   Barragan, Eva ^a   Collado, Maria ^a   Cervera, José ^a   López, José Antonio ^b   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

Genetic predisposition; Leukemia; Polymorphisms; Risk; Therapy related leukemia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ANTINEOPLASTIC AGENT; ATM PROTEIN; CHECKPOINT KINASE 2; CYTOCHROME; CYTOCHROME P450 1A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLIZING ENZYME; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GLUTATHIONE TRANSFERASE T1; GLYCINE HYDROXYMETHYLTRANSFERASE; METHIONINE SYNTHASE REDUCTASE; METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NAD); MYELOPEROXIDASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MLH1; PROTEIN MSH2; RAD51 PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; THYMIDYLATE SYNTHASE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER GROWTH; CANCER RISK; DIET; DNA REPAIR; FOLATE METABOLISM; GENE DELETION; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; LEUKEMIA; MYELODYSPLASTIC SYNDROME; PENETRANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; REVIEW; TREATMENT OUTCOME;

ANIMALS; DISEASE PROGRESSION; DNA REPAIR; ENZYMES; FOLIC ACID; HUMANS; LEUKEMIA; POLYMORPHISM, GENETIC; RISK FACTORS; VARIATION (GENETICS);

EID: 33749988447     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2006.01.016     Document Type: Review

References (112)

1. Löwenberg B., Downing J.R., and Burnet A. Acute myeloid leukemia. N Engl J Med 341 (2003) 1051-1061
2. Bonet R., and Alos I. Epidemiología descriptive. In: Delfado R.F., and Garciano J.M. (Eds). Leucemia linfoblastica aguda en la infancia (1995), Jarpyo Editores, Madrid
3. Ross J.A., Davies S.M., Potter J.D., and Robison L.L. Epidemiology of childhood leukemia, with focus on infants. Epidemiol Rev 16 (1994) 243-272
4. Pui C.H. Acute lymphoblastic leukemia in children. Curr Opin Oncol 12 (2000) 3-12
5. Greaves M. Molecular genetics of ALL. Haematologica 2000. EHA 5 Educational Book, p. 95. Available from URL: http://www.haematologica.it/free/eha5_edu_greaves.pdf.
6. Larson R.A., Wang Y., Banerjee M., Wiemels J., Hartford C., Le Beau M.M., et al. Prevalence of the inactivating 609C → T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukaemia. Blood 94 (1999) 803-807
7. Traver R.D., Horikoshi T., Danenberg K.D., Stadlbauer T.H., Danenberg P.V., Ross D., et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52 (1992) 797-802
8. Smith M.T. Benzene, NQO1, and genetic susceptibility to cancer. Proc Natl Acad Sci USA 96 (1999) 7624-7626
9. Edwards Y.H., Potter J., and Hopkinson D.A. Human FAD-dependent NAD(P)H diaphorase. Biochem J 187 (1980) 429-436
10. Rothman N., Smith M.T., Hayes R.B., Traver R.D., Hoener B., Campleman S., et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with NQO1 609C > T variation and rapid functional excretion of chlorzoxazone. Cancer Res 57 (1997) 2839-2842
11. Wan J., Shi J., Hui L., Wu D., Jin X., Zhao N., et al. Association of genetic polymorphisms in CYP2E1, MPO, NQO1, GSTM1, and GSTT1 genes with benzene poisoning. Environ Health Perspect 110 (2002) 1213-1218
12. Ng A., Taylor G.M., and Eden O.B. Treatment-related leukaemia-a clinical and scientific challenge. Cancer Treatment Rev 26 (2000) 377-391
13. Moran J.L., Siegel D., and Ross D. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity. Proc Natl Acad Sci USA 96 (1999) 8150-8155
14. Radjendirane V., Joseph P., Lee Y., Kimura S., Klein-Szantoi A.J.P., Gonzalez F.J., et al. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity. J Biol Chem 273 (1998) 7382-7389
15. Naoe T., Takeyama K., Yokozawa T., Kiyoi H., Seto M., Uike N., et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 6 (2000) 4091-4095
16. Felix C.A., Walker A.H., Lange B.J., Williams T.M., Winicki N.J., Cheung N.K.V., et al. Association of CYP3A4 genotype with treatment-related leukaemia. Proc Natl Acad Sci USA 95 (1998) 13176-13181
17. Vogelstein B., and Kinzler K.W. The genetic basis of human cancer (1998), McGraw-Hill, New York
18. Bowen D.T., Frew M.E., Rollinson S., Roddam P.L., Dring A., Smith M.T., et al. CYP1A1*2B (Val) allele is overrepresented in a subgroup of acute myeloid leukemia patients with poor-risk karyotype associated with NRAS mutation, but not associated with FLT3 internal tandem duplication. Blood 101 (2003) 2770-2774
19. Birch J.M. Genes and cancer. Arch Dis Child 80 (1999) 1-6
20. Kelly K.M., and Perentesis J.P. Polymorphisms of drug metabolizing enzymes and markers of genotoxicity to identify patients with Hodgkin's lymphoma at risk of treatment-related complications. Ann Oncol 13 Suppl 1 (2002) 34-39
21. Lan Q., Zhang L., Li G., Vermeulen R., Weinberg R.S., Dosemeci M., et al. Hematotoxicity in workers exposed to low levels of benzene. Science 306 (2004) 1774-1776
22. Pan S.S., Forrest G.L., Akman S.A., and Hu L.T. NADP(P)H: quinone oxoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res 55 (1995) 330-335
23. Krajinovic M. Further insight into the role of NQO1 in childhood leukemia. Haematologica 90 (2005) 1445
24. Eguchi-Ishimae M., Eguchi M., Ishii E., Knight D., Sadakane Y., Isoyama K., et al. Acute lymphoblastic leukemia the association of a distinctive allele of NAD(P)H:quinone oxidoreductase with pediatric acute lymphoblastic leukemias with MLL fusion genes in Japan. Haematologica 90 (2005) 1511-1515
25. Blanco J.G., Edick M.J., Hancock M.L., Winick N.J., Dervieux T., Amylon M.D., et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 12 (2002) 605-611
26. Collado M., Barragán E., Calasanz M.J., Larrayoz M.J., Colomer D., Munarriz B., et al. Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia [letter]. Leuk Res 29 (2005) 595-597
27. Sasai Y., Horiike S., Misawa S., Kaneko H., Kobayashi M., Fujii H., et al. Genotype of glutathione S-transferase and other configurations in myelodysplasia. Leuk Res 23 (1999) 975-981
28. Allan J.M., Wild ChP, Rollinson S., Willett E.V., Moorman A.V., Dovey G.J., et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy induced leukaemia. Proc Natl Acad Sci USA 98 (2001) 11592-11597
29. Seedhouse C., Faulkner R., Ashraf N., Das-Gupta E., and Russell N. Polymorphisms in genes involved in homologous recombination repair interact to increase the risk of developing acute myeloid leukemia. Clin Cancer Res 10 (2004) 2675-2680
30. Allan J.M., Smith A.G., Wheatley K., Hills R.K., Travis L.B., Hill D.A., et al. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy. Blood 104 (2004) 3872-3877
31. Worrillow L.J., Travis L.B., Smith A.G., Rollinson S., Smith A.J., Wild ChP, et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating Agents. Clin Cancer Res 9 (2003) 3012-3020
32. Smith M.T., Wang Y., Skibola C.F., Slaler D.J., Lo Nigro L., Nowell P.C., et al. Low NAD(P)H:quinone oxidoreductase activity is associated with increased risk of leukemia with MLL translocations in infants and children. Blood 100 (2002) 4590-4593
33. Wiemels J.L., Pagnamenta A., Taylor G.M., Eden O.B., Alexander F.E., and Greaves M.F. A lack of a functional NAD(P)H: quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 59 (1999) 4095-4099
34. Balta G., Yuksek N., Ozyurek E., Ertem U., Hicsonmez G., Altay C., et al. Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. Am J Hematol 73 (2003) 154-160
35. Krajinovic M., Labuda D., Richer C., Karimi S., and Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: Influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93 (1999) 1496-1501
36. Chen C.H.L., Liu Q., Pui ChH, Rivera G.K., Sandlund J.T., Ribeiro R., et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 99 (1997) 1701-1707
37. Alves S., Amorim A., Ferreira F., Norton L., and Prata M.J. The GSTM1 and GSTT1 genetic polymorphisms and susceptibility to acute lymphoblastic leukemia in children from north Portugal. Leukemia 16 (2002) 1565-1567
38. Davies S.M., Bhatia S., Ross J.A., Kiffmeyer W.R., Gaynon P.S., Radloff G.A., et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 100 (2002) 67-71
39. Kracht T., Schrappe M., Strehl S., Reiter A., Elsner H.-A., Trka J., et al. NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. Haematologica 89 (2004) 1492-1497
40. Lanciotti M., Dufour C., Corral L., Di Michele P., Pigullo S., De Rossi G., et al. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 19 (2005) 214-216
41. Skibola C.F., Smith M.T., Kane E., Roman E., Rollinson S., Raymond A., et al. Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci USA 96 (1999) 12810-12815
42. Franco R.F., Simoes B.P., Tone L.G., Gabelini S.M., Zago M.A., and Falcao R.P. The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia. Br J Haematol 115 (2001) 616-618
43. Wiemels J.L., Smith R.N., Taylor G.M., Eden O.B., Alexanderi F.E., and Mel F. Greaves, and United Kingdom Childhood Cancer Study Investigators. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukaemia. Proc Natl Acad Sci USA 98 (2001) 4004-4009
44. Krajinovic M., Lamothe S., Labuda D., Lemieux-Blanchard M., Théorêt Y., Moghrabi A., et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103 (2004) 252-257
45. Skibola C.F., Smith M.T., Hubbard A., Shane B., Roberts A.C., Law G.R., et al. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia. Blood 99 (2002) 3786-3791
46. Joseph T., Kusumakumary P., Chacko P., Abraham A., and Pillai M.R. DNA repair gene XRCC1 polymorphism in childhood acute lymphoblastic leukemia. Cancer Lett 217 (2005) 17-24
47. Krajinovic M., Labuda D., Mathonnet G., Labuda M., Moghrabi A., Champagne J., et al. Polymorphisms in genes coding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 8 (2002) 802-810
48. Aplenc R., Glatfelter W., Han P., Rappaport E., La M., Cnaan A., et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 122 (2003) 240-244
49. Stanulla M., Schrappe M., Müller-Brechlin A., Zimmermann M., and Welte K. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 95 (2000) 1222-1228
50. Rocha J.C., Cheng C., Liu W., Kishi S., Das S., Cook E.H., et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105 (2005) 4752-4758
51. Krajinovic M., Lemieux-Blanchard E., Chiasson S., Primeau M., Costea I., and Moghrabi A. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenom J 4 (2004) 66-72
52. Krajinovic M., Costea I., and Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukemia. Lancet 359 (2002) 1033-1034
53. Lauten M., Asgedom G., Welte K., Schrappe M., and Stanulla M. Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 88 (2003) 353-354
54. Smith M.T., Wang Y., Kane E., Rollinson S., Wiemels J.L., Roman E., et al. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97 (2001) 1422-1426
55. D'Alò F., Voso M.T., Guidi F., Massini G., Scardocci A., Sica S., et al. Polymorphisms of CYP1A1 and glutathione S-transferase and susceptibility to adult acute myeloid leukemia. Haematologica 89 (2004) 664-670
56. Chen H., Sandler D.P., Taylor J.A., Shore D.L., Liu E., Bloomfield C.D., et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 347 (1996) 295-297
57. Atoyebi W., Kusec R., Fidler C., Peto T.E., Boultwood J., and Wainscoat J.S. Glutathione S-transferase gene deletions in myelodysplasia. Lancet 349 (1997) 1450-1451
58. Davies S.M., Robison L.L., Buckley J.D., Radloff G.A., Ross J.A., and Perentesis J.P. Glutathione S-transferase polymorphisms in children with myeloid leukemia: a Children's Cancer Group study. Cancer Epidemiol Biomark Prev 9 (2000) 563-566
59. Rollinson S., Roddam P., Kane E., Roman E., Cartwright R., Jack A., et al. Polymorphic variation within the glutathione S-transferase genes and risk of adult acute leukaemia. Carcinogenesis 21 (2000) 43-47
60. Mehta P.A., Alonzo T.A., Gerbing R.B., Elliott J.S., Wilke T.A., Kennedy R.J., et al. XPD Lys751Gln polymorphism: etiology and outcome of childhood acute myeloid leukemia. a children's oncology group report. Blood 107 (2006) 39-45
61. Preudhomme C., Nisse C., Hebbar M., Vanrumbeke M., Brizard A., Lai J.L., et al. Glutathione S-transferase theta 1 gene defects in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. Leukemia 11 (1997) 1580-1582
62. Ross D. Metabolic basis of benzene toxicity. Eur J Haematol Suppl 60 (1996) 111-118
63. Reynolds W.F., Chang E., Douer D., Ball E.D., and Kanda V. An allelic association implicates myeloperoxidase in the etiology of acute promyelocytic leukemia. Blood 90 (1997) 2730-2737
64. Piedrafita F.J., Molander R.B., Vansant G., Vansant G., Orlova E.A., Pfahl M., et al. An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element. J Biol Chem 271 (1996) 14412-14420
65. Seidegard J., Vorachek W.R., Pero R.W., and Pearson W.R. Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are because of a gene deletion. Proc Natl Acad Sci USA 85 (1988) 7293-7297
66. Sprenger R., Schlagenhaufer R., Kerb R., Bruhn C., Brockmoller J., Roots I., et al. Characterization of the glutathione S-transferase GSTT1 deletion: discrimination of all genotypes by polymerase chain reaction indicates a trimodular genotype-phenotype correlation. Pharmacogenetics 10 (2000) 557-565
67. Ali-Osman F., Akande O., Antoun G., Mao J.X., and Buolamwini J. Molecular cloning, characterization, and expression in Escherichia coli of full-length cDNAs of three human glutathione S-transferase Pi gene variants. Evidence for differential catalytic activity of the encoded proteins. J Biol Chem 272 (1997) 10004-10012
68. Wilson M.H., Grant P.J., Hardie L.J., and Wild C.P. Glutathione S-transferase M1 null genotype is associated with a decreased risk of myocardial infarction. FASEB J 14 (2000) 791-796
69. Voso M.T., D'Alo F., Putzulu R., Mele L., Scardocci A., Chiusolo P., et al. Negative prognostic value of glutathione S-transferase (GSTM1 and GSTT1) deletions in adult acute myeloid leukemia. Blood 100 (2002) 2703-2707
70. Gonzalez C.A., Sala N., and Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 100 (2002) 249-260
71. Harries L.W., Stubbins M.J., Forman D., Howard G.C., and Wolf C.R. Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18 (1997) 641-644
72. Davies S.M., Robison L.L., Buckley J.D., Tjoa T., Woods W.G., Radloff G.A., et al. Glutathione S-transferase polymorphisms and outcome of chemotherapy in childhood acute leukemia. J Clin Oncol 19 (2001) 1279-1287
73. Yuille M., Condie A., Hudson C., Kote-Jarai Z., Stone E., Eeles R., et al. Relationship between glutathione S-transferase M1, T1, and P1 polymorphisms and chronic lymphocytic leukemia. Blood 99 (2002) 4216-4218
74. Saadat I., and Saadat M. The glutathione S-transferase mu polymorphism and susceptibility to acute lymphocytic leukemia. Cancer Lett 158 (2000) 43-45
75. Friche E., Danks M.K., and Beck W.T. Characterization of tumor cell resistance to 4′-deoxy-4′-iododoxorubicin developed in Ehrlich ascites cells in vivo. Cancer Res 52 (1992) 5701-5706
76. Ingelman-Sundberg M. Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482 (2001) 11-19
77. Kawajiri K., Nakachi K., Imai K., Yoshü A., Shinada N., and Watanabe J. Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P4501A1 gene. FEBS Lett 263 (1990) 131-133
78. Cascorbi I., Brockmoller J., and Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res 56 (1996) 2965-2969
79. Walker A.H., Jaffe J.M., Gunasegaram S., Cummings S.A., Huang C.S., Chern H.D., et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum Mutat 12 (1998) 289-293
80. Rebbeck T.R., Jaffe J.M., Walker A.H., Wein A.J., and Malkowicz S.B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90 (1998) 1225-1229
81. Amirimani B., Walker A.H., Weber B.L., and Rebbeck T.R. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 91 (1999) 1588-1590
82. Wrighton S.A., Brian W.R., Sari M.A., Iwasaki M., Guengerich F.P., Raucy J.L., et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 38 (1990) 207-213
83. Kuehl P., Zhang J., Lin Y., Lamba J., Assem M., Schuetz J., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27 (2001) 383-391
84. van Schaik R.H.N., de Wildt S.N., van Iperen N.M., Uitterlinden A.G., van den Anker J.N., and Lindemans J. CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians. Clin Chem 46 (2000) 1834-1836
85. Paris P.L., Kupelian P.A., Hall J.M., Williams T.L., Levin H., Klein E.A., et al. Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8 (1999) 901-905
86. Goyette P., Sumner J.S., Milos R., Duncan A.M., Rosenblatt D.S., Matthews R.G., et al. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat Genet 7 (1994) 195-200
87. Blount B.C., Mack M.M., Wehr C.M., McGregor J.T., Hiatt R.A., Wang G., et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci USA 94 (1997) 3290-3295
88. Engbersen A.M., Franken D.G., Boers G.H., Stevens E.M., Trijbels F.J., and Blom H.J. Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. Am J Hum Genet 56 (1995) 142-150
89. de Franchis R., Sebastio G., Mandato C., Andria G., and Mastroiacovo P. Spina bifida, 677T → C mutation, and role of folate. Lancet 346 (1995) 1703
90. van der Put N.M., Gabreels F., Stevens E.M., Smeitink J.A., Trijbels F.J., Eskes T.K., et al. A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neural-tube defects?. Am J Hum Genet 62 (1998) 1044-1051
91. Weisberg I., Tran P., Christensen B., Sibani S., and Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64 (1998) 169-172
92. Marsh S., Collie-Duguid E.S., Li T., Liu X., and McLeod H.L. Ethnic variation in the thymidylate synthase enhancer region polymorphism among Caucasian and Asian populations. Genomics 58 (1999) 310-312
93. Bailey L.B., and Folate. Methyl-related nutrients, alcohol, and the MTHFR 677C → T polymorphism affect cancer risk: Intake recommendations. J Nutr 133 (2003) 3748S-3753S
94. Marsh S., Ameyaw M.M., Githang'a J., Indalo A., Ofori-Adjei D., and McLeod H.L. Novel thymidylate synthase enhancer region alleles in African populations. Hum Mutat 16 (2000) 528
95. Taub J.W., Matherley L.H., Ravindranath Y., Kaspers G.J., Rots M.G., and Zantwijk C.H. Polymorphisms in methylenetetrahydrofolate reductase and methotrexate activity in childhood acute lymphoblastic leukemia. Leukemia 16 (2002) 764-765
96. Aplenc R., and Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia [review]. Br J Haematol 125 (2004) 421-434
97. Ulrich C.M., Yasui Y., Storb R., Schubert M.M., Wagner J.L., Bigler J., et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 98 (2001) 231-234
98. Pui C.H., Relling M.V., and Downing J.R. Mechanisms of disease. Acute lymphoblastic leukaemia. N Engl J Med 350 (2004) 1535-1548
99. Levy-Lahad E., Lahad A., Eisenberg S., Dagan E., Paperna T., Kasinetz L., et al. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA 98 (2001) 3232-3236
100. Palombo F., Iaccarino I., Nakajima E., Ikejima M., Shimada T., and Jiricny J. hMutS β, a heterodimer of hMSH2 and hMSH3, binds to insertion/deletion loops in DNA. Curr Biol 6 (1996) 1181-1184
101. Li G.M., and Modrich P. Restoration of mismatch repais to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MuL homologs. Proc Natl Acad Sci USA 92 (1995) 1950-1954
102. Lehman A.R. The xeroderma pigmentosum group D XPD gene: one gene two functions, three disease. Gene Dev 15 (2001) 15-23
103. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., et al. A single ataxia-telangiectasia gene with a product similar to PI-3 kinase. Science 268 (1995) 1749-1752
104. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 3 (2003) 155-168
105. Wu X., Webster S.R., and Chen J. Characterization of tumor-associated Chk2 mutations. J Biol Chem 276 (2001) 2971-2974
106. Meijers-Heijboer H., van den Ouweland A., Klijn J., Wasielewski M., de Snoo A., Oldenburg R., et al. Low-penetrance susceptibility to breast cancer due to CHEK2* 1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31 (2002) 55-59
107. Collado M., Landt O., Barragan E., Lass U., Cervera J., Sanz M.A., et al. Locked nucleic acid-enhanced detection of 1100delC*CHEK2 germ-line mutation in Spanish patients with hematologic malignancies. Clin Chem 50 (2004) 2201-2204
108. Vilpo J.A., Vilpo L.M., Szymkowski D.E., O'Donovan A., and Wood R.D. An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. Mol Cel Biol 15 (1995) 290-297
109. Stankovic T., Kidd A.M.J., Sutcliffe A., McGuire G.M., Robinson P., Weber P., et al. ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles: expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer. Am J Hum Genet 62 (1998) 334-345
110. Liberzon E., Avigad S., Stark B., Zilberstein J., Freedman L., Gorfine M., et al. Germ-line ATM gene alterations are associated with susceptibility to sporadic T-cell acute lymphoblastic leukemia in children. Genes Chromosom Cancer 39 (2004) 161-169
111. Buetow K.H., Edmonson M., MacDonald R., Clifford R., Yip P., Kelley J., et al. High-throughput development and characterization of a genomewide collection of gene-based single nucleotide polymorphism markers by chip-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Proc Natl Acad Sci USA 98 (2001) 581-584
112. Kammerer S., Roth R.B., Reneland R., Marnellos G., Hoyal C.R., Markward N.J., et al. Large-scale association study identifies ICAM gene region as breast and prostate cancer susceptibility locus. Cancer Res 64 (2004) 8906-8910